Bridgeway Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Bridgeway Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$702K	Hold	71,873	–	–	0.01%	793
2026 Q1	$400K	Buy	71,873 +6,000	+9%	+$45.7K	0.01%	861
2025 Q4	$485K	Buy	65,873 +31,000	+89%	+$190K	0.01%	824
2025 Q3	$228K	Sell	34,873 -2,963	-8%	-$15.9K	﹤0.01%	991
2025 Q2	$163K	Buy	+37,836	New	+$186K	﹤0.01%	1001
2025 Q1	–	Sell	-15,967	Closed	-$162K	–	1222
2024 Q4	$162K	Hold	15,967	–	–	﹤0.01%	1042
2024 Q3	$199K	Sell	15,967 -1,666	-9%	-$20.7K	﹤0.01%	1069
2024 Q2	$229K	Buy	17,633 +5,000	+40%	+$82.8K	0.01%	1026
2024 Q1	$286K	Sell	12,633 -6,667	-35%	-$117K	0.01%	1047
2023 Q4	$250K	Hold	19,300	–	–	0.01%	1090
2023 Q3	$388K	Buy	+19,300	New	+$433K	0.01%	952

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bridgeway Capital Management's KPTI Position: Q2 2026 in Review

Bridgeway Capital Management held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 71,873 shares worth $702K. The position accounts for 0.01% of the portfolio, ranked #793.

Bridgeway Capital Management first reported a position in KPTI in Q3 2023 and has held it in 11 quarters since. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Bridgeway Capital Management held 71,873 shares of Karyopharm Therapeutics worth $702K as of Q2 2026.
Bridgeway Capital Management left its Karyopharm Therapeutics share count unchanged in Q2 2026.
Karyopharm Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #793 holding.
Bridgeway Capital Management first reported a position in Karyopharm Therapeutics in Q3 2023 and has held it in 11 quarters since.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.